Immunology and immunotherapy of neuroblastoma

Seminars in Cancer Biology

Volumn 21, Issue 4, 2011, Pages 229-237

  Seeger, Robert C ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Anti GD2; Immunology; Immunotherapy; Microenvironment; Neuroblastoma

Indexed keywords

CANCER VACCINE; CD28 ANTIGEN; CD33 ANTIGEN; CETUXIMAB; DACETUZUMAB; GAMMA INTERFERON; GANGLIOSIDE GD2; GANGLIOSIDE GD2 ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; INTERLEUKIN 2 RECEPTOR ANTIBODY; INTERLEUKIN 5; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; LENALIDOMIDE; LYMPHOCYTE ANTIGEN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NERVE CELL ADHESION MOLECULE L1; RITUXIMAB; SMAD2 PROTEIN; SMAD3 PROTEIN; SURVIVIN; TRANSFORMING GROWTH FACTOR BETA1; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; BONE MARROW PURGING; CANCER CELL CULTURE; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; GENETIC ENGINEERING; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOBIOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; NATURAL KILLER CELL; NATURAL KILLER T CELL; NEUROBLASTOMA; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANIMALS; HUMANS; IMMUNOTHERAPY; NEUROBLASTOMA;

EID: 80655148904     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2011.09.012     Document Type: Review

References (150)

1. Seeger R.C., Brodeur G.M., Sather H., Dalton A., Siegel S.E., Wong K.Y., et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985, 313:1111-1116.
2. Shimada H., Stram D.O., Chatten J., Joshi V.V., Hachitanda Y., Brodeur G.M., et al. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst 1995, 87:1470-1476.
3. Schmidt M.L., Lal A., Seeger R.C., Maris J.M., Shimada H., O'Leary M., et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 2005, 23:6474-6480.
4. London W.B., Castleberry R.P., Matthay K.K., Look A.T., Seeger R.C., Shimada H., et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005, 23:6459-6465.
5. Matthay K.K., Villablanca J.G., Seeger R.C., Stram D.O., Harris R.E., Ramsay N.K., et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999, 341:1165-1173.
6. Matthay K.K., Reynolds C.P., Seeger R.C., Shimada H., Adkins E.S., Haas-Kogan D., et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children's Oncology Group Study. J Clin Oncol 2009, 27:1007-1013.
7. Yu A.L., Gilman A.L., Ozkaynak M.F., London W.B., Kreissman S.G., Chen H.X., et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010, 363:1324-1334.
8. Hellstrom I.E., Hellstrom K.E., Pierce G.E., Bill A.H. Demonstration of cell-bound and humoral immunity against neuroblastoma cells. Proc Natl Acad Sci U S A 1968, 60:1231-1238.
9. Bill A.H. The implications of immune reactions to neuroblastoma. Surgery 1969, 66:415-418.
10. Bill A.H., Morgan A. Evidence for immune reactions to neuroblastoma and future possibilities for investigation. J Pediatr Surg 1970, 5:111-116.
11. D'Angio G.J., Evans A.E., Koop C.E. Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 1971, 1:1046-1049.
12. Evans A.E., Gerson J., Schnaufer L. Spontaneous regression of neuroblastoma. Natl Cancer Inst Monogr 1976, 44:49-54.
13. Cole W.H. Spontaneous regression of cancer and the importance of finding its cause. Natl Cancer Inst Monogr 1976, 44:5-9.
14. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647.
15. Traversari C., van der Bruggen P., Luescher I.F., Lurquin C., Chomez P., Van Pel A., et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992, 176:1453-1457.
16. Boon T., Coulie P.G., Van den Eynde B.J., van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006, 24:175-208.
17. Chomez P., De Backer O., Bertrand M., De Plaen E., Boon T., Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 2001, 61:5544-5551.
18. Scanlan M.J., Gure A.O., Jungbluth A.A., Old L.J., Chen Y.T. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002, 188:22-32.
19. Corrias M.V., Scaruffi P., Occhino M., De Bernardi B., Tonini G.P., Pistoia V. Expression of MAGE-1, MAGE-3 and MART-1 genes in neuroblastoma. Int J Cancer 1996, 69:403-407.
20. Ishida H., Matsumura T., Salgaller M.L., Ohmizono Y., Kadono Y., Sawada T. MAGE-1 and MAGE-3 or -6 expression in neuroblastoma-related pediatric solid tumors. Int J Cancer 1996, 69:375-380.
21. Soling A., Schurr P., Berthold F. Expression and clinical relevance of NY-ESO-1 MAGE-1 and MAGE-3 in neuroblastoma. Anticancer Res 1999, 19:2205-2209.
22. Wolfl M., Jungbluth A.A., Garrido F., Cabrera T., Meyen-Southard S., Spitz R., et al. Expression of MHC class I MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol Immunother 2005, 54:400-406.
23. Bao L., Dunham K., Lucas K. MAGE-A1 MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing. Cancer Immunol Immunother 2011.
24. Andersen M.H., Svane I.M., Becker J.C., Straten P.T. The universal character of the tumor-associated antigen survivin. Clin Cancer Res 2007, 13:5991-5994.
25. Coughlin C.M., Fleming M.D., Carroll R.G., Pawel B.R., Hogarty M.D., Shan X., et al. Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma. J Clin Oncol 2006, 24:5725-5734.
26. Morandi F., Chiesa S., Bocca P., Millo E., Salis A., Solari M., et al. Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications. Neoplasia 2006, 8:833-842.
27. Croce M., Meazza R., Orengo A.M., Fabbi M., Borghi M., Ribatti D., et al. Immunotherapy of neuroblastoma by an interleukin-21-secreting cell vaccine involves survivin as antigen. Cancer Immunol Immunother 2008, 57:1625-1634.
28. Fest S., Huebener N., Bleeke M., Durmus T., Stermann A., Woehler A., et al. Survivin minigene DNA vaccination is effective against neuroblastoma. Int J Cancer 2009, 125:104-114.
29. Huebener N., Fest S., Strandsby A., Michalsky E., Preissner R., Zeng Y., et al. A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity. Mol Cancer Ther 2008, 7:2241-2251.
30. Huebener N., Fest S., Hilt K., Schramm A., Eggert A., Durmus T., et al. Xenogeneic immunization with human tyrosine hydroxylase DNA vaccines suppresses growth of established neuroblastoma. Mol Cancer Ther 2009, 8:2392-2401.
31. Sarkar A.K., Nuchtern J.G. Lysis of MYCN-amplified neuroblastoma cells by MYCN peptide-specific cytotoxic T lymphocytes. Cancer Res 2000, 60:1908-1913.
32. Katsanis E., Orchard P.J., Bausero M.A., Gorden K.B., McIvor R.S., Blazar B.R. Interleukin-2 gene transfer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of preestablished retroperitoneal tumors. J Immunother Emphasis Tumor Immunol 1994, 15:81-90.
33. Bausero M.A., Panoskaltsis-Mortari A., Blazar B.R., Katsanis E. Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF and interferon-gamma. J Immunother Emphasis Tumor Immunol 1996, 19:113-124.
34. Bowman L., Grossmann M., Rill D., Brown M., Zhong W.Y., Alexander B., et al. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood 1998, 92:1941-1949.
35. Bowman L.C., Grossmann M., Rill D., Brown M., Zhong W.Y., Alexander B., et al. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther 1998, 9:1303-1311.
36. Rousseau R.F., Haight A.E., Hirschmann-Jax C., Yvon E.S., Rill D.R., Mei Z., et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 2003, 101:1718-1726.
37. Russell H.V., Strother D., Mei Z., Rill D., Popek E., Biagi E., et al. Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J Immunother 2007, 30:227-233.
38. Russell H.V., Strother D., Mei Z., Rill D., Popek E., Biagi E., et al. A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma. J Immunother 2008, 31:812-819.
39. Lampson L.A., Fisher C.A. Weak HLA and beta 2-microglobulin expression of neuronal cell lines can be modulated by interferon. Proc Natl Acad Sci U S A 1984, 81:6476-6480.
40. Main E.K., Lampson L.A., Hart M.K., Kornbluth J., Wilson D.B. Human neuroblastoma cell lines are susceptible to lysis by natural killer cells but not by cytotoxic T lymphocytes. J Immunol 1985, 135:242-246.
41. Reid G.S., Shan X., Coughlin C.M., Lassoued W., Pawel B.R., Wexler L.H., et al. Interferon-gamma-dependent infiltration of human T cells into neuroblastoma tumors in vivo. Clin Cancer Res 2009, 15:6602-6608.
42. Raffaghello L., Prigione I., Airoldi I., Camoriano M., Morandi F., Bocca P., et al. Mechanisms of immune evasion of human neuroblastoma. Cancer Lett 2005, 228:155-161.
43. Raffaghello L., Prigione I., Bocca P., Morandi F., Camoriano M., Gambini C., et al. Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene 2005, 24:4634-4644.
44. Raffaghello L., Prigione I., Airoldi I., Camoriano M., Levreri I., Gambini C., et al. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 2004, 6:558-568.
45. Castriconi R., Dondero A., Augugliaro R., Cantoni C., Carnemolla B., Sementa A.R., et al. Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci U S A 2004, 101:12640-12645.
46. Leitner J., Klauser C., Pickl W.F., Stockl J., Majdic O., Bardet A.F., et al. B7-H3 is a potent inhibitor of human T-cell activation: no evidence for B7-H3 and TREML2 interaction. Eur J Immunol 2009, 39:1754-1764.
47. Morandi F., Levreri I., Bocca P., Galleni B., Raffaghello L., Ferrone S., et al. Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res 2007, 67:6433-6441.
48. Pistoia V., Morandi F., Wang X., Ferrone S. Soluble HLA-G: are they clinically relevant?. Semin Cancer Biol 2007, 17:469-479.
49. Sica A., Larghi P., Mancino A., Rubino L., Porta C., Totaro M.G., et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008, 18:349-355.
50. Metelitsa L.S. Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans. Clin Immunol 2011, 140:119-129.
51. Metelitsa L.S., Naidenko O.V., Kant A., Wu H.W., Loza M.J., Perussia B., et al. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol 2001, 167:3114-3122.
52. Metelitsa L.S., Wu H.W., Wang H., Yang Y., Warsi Z., Asgharzadeh S., et al. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med 2004, 199:1213-1221.
53. Song L., Ara T., Wu H.W., Woo C.W., Reynolds C.P., Seeger R.C., et al. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. J Clin Invest 2007, 117:2702-2712.
54. Song L., Asgharzadeh S., Salo J., Engell K., Wu H.W., Sposto R., et al. Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest 2009, 119:1524-1536.
55. Coca S., Perez-Piqueras J., Martinez D., Colmenarejo A., Saez M.A., Vallejo C., et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997, 79:2320-2328.
56. Ishigami S., Natsugoe S., Tokuda K., Nakajo A., Che X., Iwashige H., et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000, 88:577-583.
57. Villegas F.R., Coca S., Villarrubia V.G., Jimenez R., Chillon M.J., Jareno J., et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 2002, 35:23-28.
58. Menon A.G., Janssen-van Rhijn C.M., Morreau H., Putter H., Tollenaar R.A., van de Velde C.J., et al. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest 2004, 84:493-501.
59. Dall'Ozzo S., Tartas S., Paintaud G., Cartron G., Colombat P., Bardos P., et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004, 64:4664-4669.
60. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99:754-758.
61. Treon S.P., Hansen M., Branagan A.R., Verselis S., Emmanouilides C., Kimby E., et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol 2005, 23:474-481.
62. Handgretinger R., Kimmig A., Lang P., Daurer B., Kuci S., Bruchelt G., et al. Interferon-gamma upregulates the susceptibility of human neuroblastoma cells to interleukin-2-activated natural killer cells. Nat Immun Cell Growth Regul 1989, 8:189-196.
63. Foreman N.K., Rill D.R., Coustan-Smith E., Douglass E.C., Brenner M.K. Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication. Br J Cancer 1993, 67:933-938.
64. Rossi A.R., Pericle F., Rashleigh S., Janiec J., Djeu J.Y. Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. Blood 1994, 83:1323-1328.
65. Venstrom J.M., Zheng J., Noor N., Danis K.E., Yeh A.W., Cheung I.Y., et al. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res 2009, 15:7330-7334.
66. Delgado D.C., Hank J.A., Kolesar J., Lorentzen D., Gan J., Seo S., et al. Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to Hu14. 18-IL2 immunotherapy. Cancer Res 2010, 70:9554-9561.
67. Andre P., Castriconi R., Espeli M., Anfossi N., Juarez T., Hue S., et al. Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors. Eur J Immunol 2004, 34:961-971.
68. Moretta L., Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 2004, 23:255-259.
69. Lanier L.L. Natural killer cell receptor signaling. Curr Opin Immunol 2003, 15:308-314.
70. Sivori S., Parolini S., Marcenaro E., Castriconi R., Pende D., Millo R., et al. Involvement of natural cytotoxicity receptors in human natural killer cell-mediated lysis of neuroblastoma and glioblastoma cell lines. J Neuroimmunol 2000, 107:220-225.
71. Castriconi R., Dondero A., Corrias M.V., Lanino E., Pende D., Moretta L., et al. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res 2004, 64:9180-9184.
72. Truitt R.L., Piaskowski V., Kirchner P., McOlash L., Camitta B.M., Casper J.T. Immunological evaluation of pediatric cancer patients receiving recombinant interleukin-2 in a phase I trial. J Immunother (1991) 1992, 11:274-285.
73. Bauer M., Reaman G.H., Hank J.A., Cairo M.S., Anderson P., Blazar B.R., et al. A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study. Cancer 1995, 75:2959-2965.
74. Marti F., Pardo N., Peiro M., Bertran E., Amill B., Garcia J., et al. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation. Exp Hematol 1995, 23:1445-1452.
75. Bartlett J.B., Dredge K., Dalgleish A.G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004, 4:314-322.
76. Hayashi T., Hideshima T., Akiyama M., Podar K., Yasui H., Raje N., et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005, 128:192-203.
77. Berg S.L., Cairo M.S., Russell H., Ayello J., Ingle A.M., Lau H., et al. Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report. J Clin Oncol 2011, 29:316-323.
78. Bartlett J.B., Michael A., Clarke I.A., Dredge K., Nicholson S., Kristeleit H., et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 2004, 90:955-961.
79. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
80. Maloney D.G., Grillo-Lopez A.J., White C.A., Bodkin D., Schilder R.J., Neidhart J.A., et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90:2188-2195.
81. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
82. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
83. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
84. Kennett R.H., Gilbert F. Hybrid myelomas producing antibodies against a human neuroblastoma antigen present on fetal brain. Science 1979, 203:1120-1121.
85. Seeger R.C., Rosenblatt H.M., Imai K., Ferrone S. Common antigenic determinants on human melanoma, glioma, neuroblastoma, and sarcoma cells defined with monoclonal antibodies. Cancer Res 1981, 41:2714-2717.
86. Howe A.J., Seeger R.C., Molinaro G.A., Ferrone S. Analysis of human tumor cells for Ia-like antigens with monoclonal antibodies. J Natl Cancer Inst 1981, 66:827-829.
87. Seeger R.C., Danon Y.L., Rayner S.A., Hoover F. Definition of a Thy-1 determinant on human neuroblastoma, glioma, sarcoma, and teratoma cells with a monoclonal antibody. J Immunol 1982, 128:983-989.
88. Schulz G., Cheresh D.A., Varki N.M., Yu A., Staffileno L.K., Reisfeld R.A. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 1984, 44:5914-5920.
89. Honsik C.J., Jung G., Reisfeld R.A. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Proc Natl Acad Sci U S A 1986, 83:7893-7897.
90. Mujoo K., Spiro R.C., Reisfeld R.A. Characterization of a unique glycoprotein antigen expressed on the surface of human neuroblastoma cells. J Biol Chem 1986, 261:10299-10305.
91. Mujoo K., Cheresh D.A., Yang H.M., Reisfeld R.A. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res 1987, 47:1098-1104.
92. Wolff J.M., Frank R., Mujoo K., Spiro R.C., Reisfeld R.A., Rathjen F.G. A human brain glycoprotein related to the mouse cell adhesion molecule L1. J Biol Chem 1988, 263:11943-11947.
93. Cheung N.K., Saarinen U.M., Neely J.E., Landmeier B., Donovan D., Coccia P.F. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 1985, 45:2642-2649.
94. Saito M., Yu R.K., Cheung N.K. Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell. Biochem Biophys Res Commun 1985, 127:1-7.
95. Cheung N.K., Lazarus H., Miraldi F.D., Abramowsky C.R., Kallick S., Saarinen U.M., et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 1987, 5:1430-1440.
96. Moss T.J., Reynolds C.P., Sather H.N., Romansky S.G., Hammond G.D., Seeger R.C. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med 1991, 324:219-226.
97. Beiske K., Burchill S.A., Cheung I.Y., Hiyama E., Seeger R.C., Cohn S.L., et al. Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. Br J Cancer 2009, 100:1627-1637.
98. Seeger R.C., Reynolds C.P., Gallego R., Stram D.O., Gerbing R.B., Matthay K.K. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 2000, 18:4067-4076.
99. Rill D.R., Santana V.M., Roberts W.M., Nilson T., Bowman L.C., Krance R.A., et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994, 84:380-383.
100. Reynolds C.P., Seeger R.C., Vo D.D., Black A.T., Wells J., Ugelstad J. Model system for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads. Cancer Res 1986, 46:5882-5886.
101. Ladisch S., Wu Z.L. Detection of a tumour-associated ganglioside in plasma of patients with neuroblastoma. Lancet 1985, 1:136-138.
102. Wu Z.L., Schwartz E., Seeger R., Ladisch S. Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res 1986, 46:440-443.
103. Handgretinger R., Baader P., Dopfer R., Klingebiel T., Reuland P., Treuner J., et al. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14. G2a. Cancer Immunol Immunother 1992, 35:199-204.
104. Murray J.L., Cunningham J.E., Brewer H., Mujoo K., Zukiwski A.A., Podoloff D.A., et al. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 1994, 12:184-193.
105. Handgretinger R., Anderson K., Lang P., Dopfer R., Klingebiel T., Schrappe M., et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 1995, 31A:261-267.
106. Kushner B.H., Cheung N.K. Clinically effective monoclonal antibody 3F8 mediates nonoxidative lysis of human neuroectodermal tumor cells by polymorphonuclear leukocytes. Cancer Res 1991, 51:4865-4870.
107. Barker E., Mueller B.M., Handgretinger R., Herter M., Yu A.L., Reisfeld R.A. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 1991, 51:144-149.
108. Bruchelt G., Handgretinger R., Fierlbeck G., Kimmig A., Dopfer R., Reisfeld R.A., et al. Lysis of neuroblastoma cells by the ADCC-reaction: granulocytes of patients with chronic granulomatous disease are more effective than those of healthy donors. Immunol Lett 1989, 22:217-220.
109. Hank J.A., Robinson R.R., Surfus J., Mueller B.M., Reisfeld R.A., Cheung N.K., et al. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res 1990, 50:5234-5239.
110. Kushner B.H., Cheung N.K. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 1989, 73:1936-1941.
111. Barker E., Reisfeld R.A. A mechanism for neutrophil-mediated lysis of human neuroblastoma cells. Cancer Res 1993, 53:362-367.
112. Metelitsa L.S., Gillies S.D., Super M., Shimada H., Reynolds C.P., Seeger R.C. Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis. Blood 2002, 99:4166-4173.
113. Hank J.A., Surfus J., Gan J., Chew T.L., Hong R., Tans K., et al. Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother Emphasis Tumor Immunol 1994, 15:29-37.
114. Frost J.D., Hank J.A., Reaman G.H., Frierdich S., Seeger R.C., Gan J., et al. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14. G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer 1997, 80:317-333.
115. Yu A.L., Uttenreuther-Fischer M.M., Huang C.S., Tsui C.C., Gillies S.D., Reisfeld R.A., et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 1998, 16:2169-2180.
116. Ozkaynak M.F., Sondel P.M., Krailo M.D., Gan J., Javorsky B., Reisfeld R.A., et al. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J Clin Oncol 2000, 18:4077-4085.
117. Gilman A.L., Ozkaynak M.F., Matthay K.K., Krailo M., Yu A.L., Gan J., et al. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. J Clin Oncol 2009, 27:85-91.
118. Sabzevari H., Gillies S.D., Mueller B.M., Pancook J.D., Reisfeld R.A. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci U S A 1994, 91:9626-9630.
119. Pancook J.D., Becker J.C., Gillies S.D., Reisfeld R.A. Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2. Cancer Immunol Immunother 1996, 42:88-92.
120. Becker J.C., Varki N., Gillies S.D., Furukawa K., Reisfeld R.A. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J Clin Invest 1996, 98:2801-2804.
121. Osenga K.L., Hank J.A., Albertini M.R., Gan J., Sternberg A.G., Eickhoff J., et al. A phase I clinical trial of the hu14. 18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res 2006, 12:1750-1759.
122. Shusterman S., London W.B., Gillies S.D., Hank J.A., Voss S.D., Seeger R.C., et al. Antitumor activity of hu14. 18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol 2010, 28:4969-4975.
123. Hernandez-Ilizaliturri F.J., Reddy N., Holkova B., Ottman E., Czuczman M.S. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 2005, 11:5984-5992.
124. Wu L., Adams M., Carter T., Chen R., Muller G., Stirling D., et al. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008, 14:4650-4657.
125. Zhang L., Qian Z., Cai Z., Sun L., Wang H., Bartlett J.B., et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 2009.
126. Tai Y.T., Li X.F., Catley L., Coffey R., Breitkreutz I., Bae J., et al. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res 2005, 65:11712-11720.
127. Lapalombella R., Gowda A., Joshi T., Mehter N., Cheney C., Lehman A., et al. The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. Br J Haematol 2009, 144:848-855.
128. Wu L., Parton A., Lu L., Adams M., Schafer P., Bartlett J.B. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. Cancer Immunol Immunother 2011, 60:61-73.
129. Sadelain M. T-cell engineering for cancer immunotherapy. Cancer J 2009, 15:451-455.
130. Krause A., Guo H.F., Latouche J.B., Tan C., Cheung N.K., Sadelain M. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med 1998, 188:619-626.
131. Rossig C., Bollard C.M., Nuchtern J.G., Merchant D.A., Brenner M.K. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer 2001, 94:228-236.
132. Rossig C., Bollard C.M., Nuchtern J.G., Rooney C.M., Brenner M.K. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 2002, 99:2009-2016.
133. Pule M.A., Savoldo B., Myers G.D., Rossig C., Russell H.V., Dotti G., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008, 14:1264-1270.
134. Gonzalez S., Naranjo A., Serrano L.M., Chang W.C., Wright C.L., Jensen M.C. Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma. J Gene Med 2004, 6:704-711.
135. Park J.R., Digiusto D.L., Slovak M., Wright C., Naranjo A., Wagner J., et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007, 15:825-833.
136. Craddock J.A., Lu A., Bear A., Pule M., Brenner M.K., Rooney C.M., et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother 2010, 33:780-788.
137. Sun J., Dotti G., Huye L.E., Foster A.E., Savoldo B., Gramatges M.M., et al. T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms. Mol Ther 2010, 18:2006-2017.
138. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., McNearney S.A., Yun G.H., Fautsch S.K., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051-3057.
139. Rubnitz J.E., Inaba H., Ribeiro R.C., Pounds S., Rooney B., Bell T., et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010, 28:955-959.
140. Somanchi S.S., Senyukov V.V., Denman C.J., Lee D.A. Expansion, purification, and functional assessment of human peripheral blood NK cells. J Vis Exp 2011.
141. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010, 11:889-896.
142. Mantovani A. B cells and macrophages in cancer: yin and yang. Nat Med 2011, 17:285-286.
143. Asgharzadeh S., Pique-Regi R., Sposto R., Wang H., Yang Y., Shimada H., et al. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst 2006, 98:1193-1203.
144. Trotta R., Col J.D., Yu J., Ciarlariello D., Thomas B., Zhang X., et al. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol 2008, 181:3784-3792.
145. Bellone G., Aste-Amezaga M., Trinchieri G., Rodeck U. Regulation of NK cell functions by TGF-beta 1. J Immunol 1995, 155:1066-1073.
146. Andreu P., Johansson M., Affara N.I., Pucci F., Tan T., Junankar S., et al. FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 2010, 17:121-134.
147. DeNardo D.G., Andreu P., Coussens L.M. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev 2010, 29:309-316.
148. Johnson B.D., Jing W., Orentas R.J. CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma. J Immunother 2007, 30:203-214.
149. Croce M., Corrias M.V., Orengo A.M., Brizzolara A., Carlini B., Borghi M., et al. Transient depletion of CD4(+) T cells augments IL-21-based immunotherapy of disseminated neuroblastoma in syngeneic mice. Int J Cancer 2010, 127:1141-1150.
150. Jing W., Yan X., Hallett W.H., Gershan J.A., Johnson B.D. Depletion of CD25+ T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma. Blood 2011, 117:6952-6962.